New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
06:16 EDTSNTASynta Pharmaceuticals announces positive interim results from ganetespib trial
Synta Pharmaceuticals announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The ENCHANT-1 trial was designed to evaluate ganetespib single agent activity in metastatic breast cancer and identify potential predictive biomarkers. Target enrollment is 35 patients in three cohorts, which include HER2+ breast cancer, triple-negative breast cancer, and, recently added and now recruiting, ER/PR-positive patients previously untreated for locally advanced or metastatic disease. The goal of the trial design is to obtain initial evidence of a clinical activity signal with single-agent ganetespib administered for up to 12 weeks. Professor David Cameron, Professor of Oncology and Director of Cancer Services, NHS Lothian stated, “Ganetespib appears to not only overcome the challenges of earlier-generation Hsp90 inhibitors, with a good tolerability profile, but demonstrates highly encouraging single-agent activity in both HER2+ and triple-negative disease. These results warrant expanded study of ganetespib in this metastatic disease setting.”
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:04 EDTSNTASynta Pharmaceuticals presents preclinical results from Hsp90 platform
Synta Pharmaceuticals announced that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona. “This poster highlights our ongoing evaluation of multiple candidates from the HDC platform. The preclinical results for our lead candidates not only demonstrate broad activity across several tumor types, but also the ability for HDCs to induce prolonged antitumor effects as compared to well-established cytotoxic agents,” said Weiwen Ying, Vice President, Discovery Chemistry at Synta. “In addition, the platform is not limited to using traditional cytotoxic therapeutics as payloads. A number of commonly used small molecule anticancer agents may also be incorporated, including tyrosine kinase inhibitors, proteosome inhibitors, small molecule immunotherapeutics, and other molecularly targeted agents. By leveraging the preferential retention characteristic of the Hsp90 targeting arm of an HDC in tumors, intratumoral exposure and antitumor potency for a wide array of payloads can be potentially improved." "We are encouraged by the progress the team has achieved to date with candidates arising from the HDC platform and the promise that the platform holds for both internal development and partnerships,” said Anne Whitaker, President and CEO of Synta. “We continue to evaluate options for efficiently advancing candidates from this platform and look forward to providing updates in the future.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use